Efficacy and Safety of Antiviral Therapy

Dear Colleagues,

During the last years, a great effort has been made to improve antiviral treatments. Also, new strategies are at the door.

SARS-CoV-2 has been a testing ground for new treatment strategies developed in a very short time frame, with apparently few mild adverse events reported. Additionally, antiretroviral therapy (ART) has embraced new molecules and new formulations, with the first injective ART already available in many countries for the treatment of HIV. Furthermore, interesting breakthroughs have been made in the field of hepatitis, creating the chance of hepatitis C eradication in the foreseeable future. Moreover, the first treatment for hepatitis delta has been introduced. Finally, regarding Herpesviridae, new strategies are being developed, including genomic editing techniques, and new drugs have already been introduced.

All these new treatment strategies and others that are not mentioned in the above paragraph have been shown to be extremely promising in clinical trials. However, further real-life studies are needed to better assess the efficacy, the burden of adverse events and their pathophysiological mechanisms.

Prof. Dr. Giordano Madeddu
Dr. Andrea De Vito
Dr. Agnese Colpani
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.